DUBLIN--(BUSINESS WIRE)--The "Global Pulmonary Arterial Hypertension Market Research 2023": Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and ...
Panelists discuss how sotatercept represents a paradigm shift as the first activin signaling inhibitor showing dramatic improvements in heavily pretreated patients, with the Stellar and Zenith trials ...
In a recent review, researchers overviewed the challenging aspects of treating pulmonary arterial hypertension (PAH), highlight the genetic and etiological variability, and advocate for research to ...
Please provide your email address to receive an email when new articles are posted on . In PAH lung samples, researchers observed elevated asporin levels and found a link between these levels and ...
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically ...
LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global pulmonary hypertension (PAH) drugs market is projected to grow to USD 4,782.81 million by 2021, at a ...
Pulmonary hypertension is characterized by increased BP in the pulmonary vasculature You will want your patients to consult a specialist to slow progression of this debilitating disease. Here's what ...
Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...
In a new report, the Midwest Institute for Clinical and Economic Review's (ICER) Comparative Effectiveness Public Advisory Council concluded that the Merck drug sotatercept, currently under review by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results